Skip to main content

Eurofins Acquires Dutch MDx, Pathology Lab

NEW YORK (360DX) – Eurofins Scientific today announced the acquisition of NMDL-LCPL, a specialized medical testing business in the Netherlands providing molecular diagnostics and pathology services.

Financial and other terms of the deal were not disclosed.

NMDL-LCPL, which is comprised of the Nederlands Moleculair Diagnostisch Laboratorium and the Leids Cytologisch Pathologisch Laboratorium, serves more than 2,000 general practitioners, as well as hospitals, independent treatment centers and other laboratories, with a particularly strong presence in the Southwestern part of the Netherlands.

NMDL is a molecular diagnostic services lab, offering molecular virology and bacteriology testing. LCPL is the largest pathology laboratory for general practitioners in the Netherlands and offers advanced pathology services, including cervical cytology and molecular biological tests.

Through NMDL's selection as one of the companies to execute the bevolkingsonderzoek (BVO) for the Dutch national cervical cancer screening program, NMDL performs high volume molecular diagnostic HPV testing. A portion of the samples requiring follow-up pathology screening are performed by LCPL.

The acquisition of NMDL-LCPL provides Paris-based Eurofins Scientific with a platform for further growth of its clinical diagnostics testing portfolio in the Netherlands. Following the acquisition of Labo Van Poucke earlier this month, the acquisition further strengthens Eurofins Scientific's presence in the Benelux region, according to the company.

"We look forward to further leveraging our newly-acquired clinical diagnostics platforms in the Benelux region to the benefit of medical practitioners and their patients," Eurofins Scientific CEO Gilles Martin said, in a statement.